Literature DB >> 10402233

Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials.

T C Hsieh1, P Burfeind, K Laud, J M Backer, F Traganos, Z Darzynkiewicz, J M Wu.   

Abstract

Trans-resveratrol, a polyphenol present in red wines and various human foods, is an antioxidant also with reported chemopreventive properties. However, whether resveratrol may exert different effects in malignant cells with a common anatomical origin yet displaying different invasive characteristics is not known. Since invasiveness and metastasis are considered to be the most insidious and life-threatening aspects for all cancers, we compared the ability of resveratrol to control growth and cell cycle transition in the highly invasive MDA-MB-435 with the minimally invasive MCF-7 breast carcinoma cells. The data revealed that resveratrol exerted a greater inhibitory effect on the MDA-MB-435 cells. A diminution of percentage of cells in G1 phase and a corresponding accumulation of cells in S phase of the cell cycle was observed. We also studied the effect of resveratrol on a panel of MDA-MB-435 cells transfected with nm23-H1 and nm23-H2 genes, which have been suggested to play a role in controlling metastasis in breast cancer cells. These cells are designated as Vbeta, 1beta, 1Tbeta, 2beta, and 2Tbeta, respectively. The control Vbeta consists of MDA-MB-435 cells transfected with bacterial beta-glucuronidase. Cells labeled 1beta and 1Tbeta correspond to those carrying beta-glucuronidase and overexpressed wild-type (His118) or mutant (Tyr118, catalytically inactive) nm23-H1 genes. The 2beta and 2Tbeta refer to cells transfected with wild-type and mutant nm23-H2 genes. The responses of these cells to resveratrol were assessed by measuring proliferation, cell cycle phase distribution, and changes in expression of several genes. These studies have shown that resveratrol (25 microM, 3 days) reduced growth of all cell types by 60-80%. Overexpression of both wild-type and catalytically inactive nm23-H1 (1beta, 1Tbeta) but not nm23-H2 (2beta, 2Tbeta) reduced the proportion of cells in G1 phase, compared to the Vbeta control cells. Little changes in expression of PCNA, Rb, p53, and bcl-2 were observed in the five cell types treated with resveratrol, compared to untreated cells. Noted exceptions included reduced expression of Rb protein and increased expression of p53 in 2beta and 2Tbeta cells, and increased expression of bcl-2 in 2beta cells, treated with resveratrol. In contrast, resveratrol upregulated expression of cathepsin D by 50-100% in all cell lines except 1beta. These results suggest that the intrinsic metastatic potential of cancer cells may affect their responses to chemopreventive agents such as resveratrol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10402233     DOI: 10.3892/ijo.15.2.245

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin.

Authors:  Tze-Chen Hsieh; Joseph M Wu
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

2.  Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells.

Authors:  Francesca De Amicis; Francesca Giordano; Adele Vivacqua; Michele Pellegrino; Maria Luisa Panno; Donatella Tramontano; Suzanne A W Fuqua; Sebastiano Andò
Journal:  FASEB J       Date:  2011-07-07       Impact factor: 5.191

3.  Resveratrol prolongs allograft survival after liver transplantation in rats.

Authors:  Sheng-Li Wu; Liang Yu; Ke-Wei Meng; Zhen-Hua Ma; Cheng-En Pan
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

4.  Inhibition of mammalian DNA polymerases by resveratrol: mechanism and structural determinants.

Authors:  Giada A Locatelli; Monica Savio; Luca Forti; Igor Shevelev; Kristijan Ramadan; Lucia A Stivala; Vanio Vannini; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

5.  Resveratrol-induced gene expression profiles in human prostate cancer cells.

Authors:  Sunita B Jones; Samuel E DePrimo; Michael L Whitfield; James D Brooks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

6.  Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells.

Authors:  Nicolas G Azios; Suranganie F Dharmawardhane
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

Review 7.  Resveratrol: a review of preclinical studies for human cancer prevention.

Authors:  Mohammad Athar; Jung Ho Back; Xiuwei Tang; Kwang Ho Kim; Levy Kopelovich; David R Bickers; Arianna L Kim
Journal:  Toxicol Appl Pharmacol       Date:  2007-01-03       Impact factor: 4.219

Review 8.  Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence.

Authors:  Ana Cláudia Santos; Irina Pereira; Mariana Magalhães; Miguel Pereira-Silva; Mariana Caldas; Laura Ferreira; Ana Figueiras; António J Ribeiro; Francisco Veiga
Journal:  AAPS J       Date:  2019-04-23       Impact factor: 4.009

9.  Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment.

Authors:  Vanna Sanna; Imtiaz Ahmad Siddiqui; Mario Sechi; Hasan Mukhtar
Journal:  Mol Pharm       Date:  2013-09-04       Impact factor: 4.939

10.  An analogue of resveratrol HS-1793 exhibits anticancer activity against MCF-7 cells via inhibition of mitochondrial biogenesis gene expression.

Authors:  Seung Hun Jeong; In Sung Song; Hyoung Kyu Kim; Sung Ryul Lee; Suhee Song; Hongsuk Suh; Young Geol Yoon; Young Hyun Yoo; Nari Kim; Byoung Doo Rhee; Kyung Soo Ko; Jin Han
Journal:  Mol Cells       Date:  2012-10-18       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.